Clinical Trials
16 trialsNCT02557321 2023-11-21
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
Provectus Pharmaceuticals
Phase 1/2 Unknown
NCT04546074 2023-10-03
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
Keio University
Phase 1/2 Unknown
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT05127590 2023-07-03
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
Ribon Therapeutics, Inc.
Phase 1/2 Unknown
NCT05175235 2023-03-03
Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
National University Hospital, Singapore
Phase 1/2 Unknown
NCT05541445 2022-09-15
Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Unknown
NCT04262427 2022-08-23
CAPER
The Christie NHS Foundation Trust
Phase 1/2 Unknown
NCT05053880 2021-11-19
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
Accendatech USA Inc.
Phase 1/2 Unknown
NCT02305186 2021-08-13
UVA-PC-PD101
University of Virginia
Phase 1/2 Unknown
NCT02901301 2021-04-06
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
Yonsei University
Phase 1/2 Unknown
NCT04699643 2021-01-07
FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors
EverNov Medicines (Zhuhai Hengqin) Co., Ltd
Phase 1/2 Unknown
NCT03525782 2018-05-16
Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
The First Affiliated Hospital of Guangdong Pharmaceutical University
Phase 1/2 Unknown
NCT02758587 2018-03-19
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
NHS Greater Glasgow and Clyde
Phase 1/2 Unknown
NCT03446911 2018-02-27
Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery
Amsterdam UMC, location VUmc
Phase 1/2 Unknown
NCT02990416 2016-12-13
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
Virogen Biotechnology Inc.
Phase 1/2 Unknown
NCT02430363 2016-02-24
Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
Medical Research Council
Phase 1/2 Unknown